3 results
Approved WMOCompleted
"The primary objective of this study is to compare the clinical therapeutic effects of intravenous DP-b99 at adose of 1.0 mg/kg initiated within nine hours of stroke onset and administered daily over 2 hours for 4consecutive days versus placebo…
Approved WMOCompleted
Induction Phase (IP)* To independently evaluate the efficacy of etrolizumab dose regimens compared with placebo in inducing clinical remission and endoscopic improvement at the end of the Induction Phase (Week 14)Maintenance Phase (MP)* To…
Approved WMOCompleted
To assess the influence of dosing guided by AutoK on achieving PK targets and clinical endpoints in intensive care patients with sepsis.